Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this exploratory imaging study is to further characterize [18F]T807,
an investigational PET radioligand for imaging Tau (thought to be a downstream biomarker
indicative of neurodegeneration in conditions such as AD).
Phase:
Phase 1
Details
Lead Sponsor:
Molecular NeuroImaging
Collaborators:
Institute for Neurodegenerative Disorders Roche Pharma AG